Showing 4831-4840 of 7317 results for "".
- Survey Shows Common Skin Cancer Terms Often Misunderstoodhttps://practicaldermatology.com/news/common-skin-cancer-terms-often-misunderstood-survey-finds/2484880/A research letter looking at how well patients understand commonly used terminology related to skin published in JAMA Dermatology revealed significant gaps that could hinder informed decision-making, according to the study r
- MEL-SELF Analysis: Comparable Outcomes Between Affordable and Premium Dermatoscopeshttps://practicaldermatology.com/news/analysis-shows-comparable-outcomes-between-affordable-and-premium-dermatoscopes/2484733/A new randomized study embedded within the MEL-SELF trial suggests both low-cost and high-cost dermatoscopes enabled patients with a history of early-stage melanoma to effectively capture images for remote dermatologic assessment.
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- SCRATCH-AD: Rapid-Onset Anti-Itch and Anti-Inflammatory Effects of Ruxolitinib Creamhttps://practicaldermatology.com/news/scratch-ad-rapid-onset-anti-itch-and-anti-inflammatory-effects-of-ruxolitinib-cream/2484591/Results from the SCRATCH-AD study suggested that ruxolitinib cream 1.5% provided itch relief, as well as broader improvements in atopic dermatitis (AD) severity The SCRATCH-AD study evaluated how quickly ruxolitinib 1.5% cream
- Stapokibart Shows Efficacy and Safety in Elderly Patients With ADhttps://practicaldermatology.com/news/stapokibart-shows-efficacy-and-safety-in-elderly-patients-with-ad/2484589/This post hoc analysis evaluated the efficacy and safety of stapokibart, an anti–IL-4Rα monoclonal antibody, in elderly adults with moderate-to-severe atopic dermatitis—a population often characterized by more complex inflammatory signatures and comorbidities. The
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- NIH Grants for Vitiligo Research Rise Over Time, Driven by Medical Schools and NIAMShttps://practicaldermatology.com/news/nih-grants-for-vitiligo-research-rise-over-time-driven-by-medical-schools-and-niams/2484513/Funding trends National Institutes of Health (NIH) funding trends shows steady, long-term support for vitiligo research from 1985 through 2024, according to a new analysis. Using the NIH Research Portfolio Online Reporting To
- Study: Itch and Rash Severity Linked to Biologic Use in Eczemahttps://practicaldermatology.com/news/itch-and-rash-severity-linked-to-biologic-use-in-eczema-paper/2484499/Data from a recent pre-proof in the Journal of the American Academy of Dermatology highlights that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic de
- FDA Accepts sNDA for ZORYVE Cream 0.3% in Children Aged 2 to 5https://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-03-in-children-ages-25/2484497/The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) seeking an expanded indication for ZORYVE® (roflumilast) cream 0.3% to include children ages 2 to 5 with plaque psoriasis.
- Large Study Shows No Link Found Between Pemphigus and Psychiatric Disordershttps://practicaldermatology.com/news/large-study-shows-no-link-found-between-pemphigus-and-psychiatric-disorders/2484421/Results from a large retrospective cohort study analyzing more than 120 million U.S. electronic health records found no increased risk of psychiatric disorders in patients with pemphigus. "While 10–15% of dermatology patients ar